Multivalent DTP-POLIO vaccines

Abstract

A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide of Haemophilus influenzae type b and tetanus toxoid or diphteria toxoid, which may be reconstituted from a lyophilized state by the other components of the vaccine. The administration of the multiple component vaccine results in no diminution in the immunogenicity of any component as a result of interference by other components of the vaccine.

Description

This application is a divisional application of an invention patent application with an application date of July 2, 1997, an application number of 97197609.0, and an invention title of "multivalent DTP-POLIO vaccine". field of invention The present invention relates to multivalent vaccines, in particular multivalent vaccines for pediatric administration. Referenced related applications This application is a continuation-in-part of co-pending U.S. Patent Application No. 08 / 501,743 filed July 12, 1995, which itself is a co-pending U.S. Patent Application No. filed May 4, 1995. Part of 08 / 433,646 continued application. Background of the invention Pertussis is a severe, highly contagious upper respiratory tract infection caused by the bacterium Bordetella pertussis (B. pertussis). The World Health Organization estimates that there are 60 million cases of pertussis each year, resulting in 500,000 to 1 million deaths (Ref. 1. Throughout this specification, various references...

AI Technical Summary

Problems solved by technology

Currently available commercial combination vaccines may not contain appropriate formulations of the appropriate antigens in the appropriate immunogenic form to achieve the required level of efficacy in pertussis-susceptible populations

Images